165 related articles for article (PubMed ID: 33375459)
21. Complementary and alternative medicine (CAM) in headache of children and adolescents: open-label Italian study.
Onofri A; Necozione S; Tozzi E
Clin Ter; 2020; 171(5):e393-e398. PubMed ID: 32901780
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of nutraceuticals in migraine prophylaxis.
D'Onofrio F; Raimo S; Spitaleri D; Casucci G; Bussone G
Neurol Sci; 2017 May; 38(Suppl 1):117-120. PubMed ID: 28527067
[TBL] [Abstract][Full Text] [Related]
23. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial.
Gaul C; Diener HC; Danesch U;
J Headache Pain; 2015; 16():516. PubMed ID: 25916335
[TBL] [Abstract][Full Text] [Related]
24. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.
Buse DC; Lipton RB; Hallström Y; Reuter U; Tepper SJ; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
Cephalalgia; 2018 Sep; 38(10):1622-1631. PubMed ID: 30086681
[TBL] [Abstract][Full Text] [Related]
25. Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire.
Dowson AJ; Tepper SJ; Baos V; Baudet F; D'Amico D; Kilminster S
Curr Med Res Opin; 2004 Jul; 20(7):1125-35. PubMed ID: 15265257
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of 10 kHz Spinal Cord Stimulation for the Treatment of Refractory Chronic Migraine: A Prospective Long-Term Open-Label Study.
Al-Kaisy A; Palmisani S; Carganillo R; Wesley S; Pang D; Rotte A; Santos A; Lambru G
Neuromodulation; 2022 Jan; 25(1):103-113. PubMed ID: 35041579
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
29. Validation of the Korean Migraine-Specific Quality of Life Questionnaire Version 2.1 in Episodic and Chronic Migraine.
Seo JG; Park SP
J Oral Facial Pain Headache; 2017 Summer; 31(3):251-256. PubMed ID: 28738110
[TBL] [Abstract][Full Text] [Related]
30. Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate.
Mathew NT; Kailasam J; Meadors L
Headache; 2002 Sep; 42(8):796-803. PubMed ID: 12390644
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety.
Boudreau GP; Grosberg BM; McAllister PJ; Lipton RB; Buse DC
Int J Gen Med; 2015; 8():79-86. PubMed ID: 25733924
[TBL] [Abstract][Full Text] [Related]
32. The Efficacy of Herbal Supplements and Nutraceuticals for Prevention of Migraine: Can They Help?
Kaur K; Hernandez V; Al Hajaj SW; Ebrahim AM; Razack M; ElSharief MW; Dragas D
Cureus; 2021 May; 13(5):e14868. PubMed ID: 33972917
[TBL] [Abstract][Full Text] [Related]
33. Preventing Episodic Migraine With Caloric Vestibular Stimulation: A Randomized Controlled Trial.
Wilkinson D; Ade KK; Rogers LL; Attix DK; Kuchibhatla M; Slade MD; Smith LL; Poynter KP; Laskowitz DT; Freeman MC; Hoffer ME; Saper JR; Scott DL; Sakel M; Calhoun AH; Black RD
Headache; 2017 Jul; 57(7):1065-1087. PubMed ID: 28656612
[TBL] [Abstract][Full Text] [Related]
34. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
[TBL] [Abstract][Full Text] [Related]
35. The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial.
Ghorbani Z; Rafiee P; Fotouhi A; Haghighi S; Rasekh Magham R; Ahmadi ZS; Djalali M; Zareei M; Razeghi Jahromi S; Shahemi S; Mahmoudi M; Togha M
J Headache Pain; 2020 Feb; 21(1):22. PubMed ID: 32093657
[TBL] [Abstract][Full Text] [Related]
36. An observational study of fixed-dose Tanacetum parthenium nutraceutical preparation for prophylaxis of pediatric headache.
Moscano F; Guiducci M; Maltoni L; Striano P; Ledda MG; Zoroddu F; Raucci U; Villa MP; Parisi P
Ital J Pediatr; 2019 Mar; 45(1):36. PubMed ID: 30871574
[TBL] [Abstract][Full Text] [Related]
37. Reduction in Migraine and Headache Frequency and Intensity With Combined Antioxidant Prophylaxis (N-acetylcysteine, Vitamin E, and Vitamin C): A Randomized Sham-Controlled Pilot Study.
Visser EJ; Drummond PD; Lee-Visser JLA
Pain Pract; 2020 Sep; 20(7):737-747. PubMed ID: 32306462
[TBL] [Abstract][Full Text] [Related]
38. Prevention of episodic migraine with topiramate: a prospective 24-week, open-label, flexible-dose clinical trial with optional 24 weeks follow-up in a community setting.
Malessa R; Gendolla A; Steinberg B; Schmitt L; Bornhoevd K; Djelani M; Schäuble B;
Curr Med Res Opin; 2010 May; 26(5):1119-29. PubMed ID: 20225996
[TBL] [Abstract][Full Text] [Related]
39. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
40. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
